Immunocore Kernkompetenz: 100% Chance fürs Leben
Seite 1 von 4 Neuester Beitrag: 25.09.24 08:45 | ||||
Eröffnet am: | 05.02.21 11:16 | von: iTechDachs | Anzahl Beiträge: | 97 |
Neuester Beitrag: | 25.09.24 08:45 | von: Vassago | Leser gesamt: | 37.627 |
Forum: | Hot-Stocks | Leser heute: | 8 | |
Bewertet mit: | ||||
Seite: < | 2 | 3 | 4 > |
- gegen Bakterien
- gegen Viren
- gegen den eigenen Körper
mit dessen eigenen Mitteln zu gewinnen: T-Zellrezeptoren (TCR)
Immunocore - die TCR Company
Mit rund 10 Millionen ADR Aktien zu einem Ausgabekurs von $26 um 258 Millionen US Dollar Cash bei einer Marktkapitalisierung von etwas über einer Milliarden US Dollar.
Für dieses Geld bekommen die Aktionäre einen Anteil an einem 2008 als Ausgründung der Medigene AG von deren britischen Zukauf Avidex gestarteten und nun bis zur ersten abgeschlossenen Phase III fortgeschrittenen Unternehmen mit vielen "Firsts" :
$IMCR -story is groundbreaking on multiple fronts: First pos P3 survival data for a CD3 T cell engager in a solid tumor, first effective IO in uveal mel, first TCR based win in a randomized trial, first effective treatment targeting gp100 after years of failures. Well done!
— Ohad Hammer (@ohadhammer) January 18, 2021
bis zum 9-ten Februar mit Zeichnung der Optionen: $42
Meine Spekulationen - KEINE Handelsempfehlung!
Zeitpunkt: 07.02.21 10:52
Aktion: Löschung des Beitrages
Kommentar: Moderation auf Wunsch des Verfassers
https://www.nasdaq.com/market-activity/stocks/imcr/real-time
--
Schon eine beeindruckende Pipeline. Bei einem IPO gibt es wohl selten eine fertige P3 zu sehen.
Pipeline Stand heute, mal festhalten;
https://www.immunocore.com/our-science/pipeline
Goldman Neutral $40
Jefferies Buy $65
JP Morgan Overweight $58
Da könnte was in beide Richtungen gehen ...
12 April 2021 at 4:30 PM EDT
Download PDF
PRESS RELEASE
Immunocore presents phase 3 data comparing tebentafusp with investigator’s choice in the clinical trial plenary session at the
American Association for Cancer Research 2021 Annual Meeting
"Tebentafusp is the first investigational therapy to improve Overall Survival (OS) in patients with metastatic uveal melanoma
First positive Phase 3 clinical trial for any T cell receptor therapeutic and first for any bispecific in a solid tumor
(OXFORDSHIRE, England & CONSHOHOCKEN, Penn. & ROCKVILLE, Md., US, 12 April 2021) Immunocore (Nasdaq: IMCR), a late-stage biotechnology company pioneering the development of a novel class of T cell receptor (TCR) bispecific immunotherapies designed to treat a broad range of diseases, including cancer, infectious and autoimmune disease, presented data from a phase 3 randomized trial comparing tebentafusp (IMCgp100) with investigator’s choice in first-line metastatic uveal melanoma (mUM) in the clinical trial plenary session at the American Association for Cancer Research (AACR) Annual Meeting 2021.
Tebentafusp demonstrated a statistically significant and clinically meaningful improvement in overall survival (OS) as a first-line treatment in mUM. The OS Hazard Ratio (HR) in the intent-to-treat population favored tebentafusp, HR=0.51 (95% CI: 0.37, 0.71); p< 0.0001, over investigator’s choice (82% pembrolizumab; 12% ipilimumab; 6% dacarbazine). Treatment-related adverse events were manageable and consistent with the proposed mechanism..."
https://ir.immunocore.com/news-releases/...data-comparing-tebentafusp
wie Immunocore schon in der Pressemitteilung zum letzten Quartalsbericht und ausführlicher im Jahresbericht Seite 127 beschrieben hatte: "Under the GSK Agreement, we granted GSK the right to nominate up to four targets as being exclusive to GSK under our collaboration. The first target, GSK01/NY-ESO, was nominated at the time of execution of the GSK Agreement. A second target was nominated in July 2017. GSK has no further ability to nominate additional targets under the GSK Agreement. Under the GSK Agreement, for NY-ESO, we are responsible for the development of the soluble TCR bispecific therapeutic candidate compounds through initial Phase 1 clinical trials. The GSK-01 NY-ESO Phase 1 dose escalation study to determine safety, and which is enrolling several different tumor types, is still ongoing. An expansion phase was planned to initiate once the Phase 1 dose escalation was complete. However, following a portfolio review, we, in collaboration with GSK, have jointly elected not to plan for or initiate the efficacy determining expansion phase. The expansion arm was planned to be conducted in synovial sarcoma, an ultra-rare disease which is already addressed by other assets in our portfolio including MAGE-A4 and PRAME. Consequently, GSK has forgone their option to acquire an exclusive license to the NY-ESO program and we will retain ownership of the asset. We will present the data from this Phase 1 study in 2022."